Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) FDA approval marks a...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept PR...
Filed by Mylan N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...
England 0001623613 false 0001623613 2020-05-29 2020-05-29 UNITED STATES SECURITIES AND...
- First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX®, potentially giving Mylan access to 14 indications...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...
false 0001623613 0001623613 2020-05-29 2020-05-29 UNITED STATES SECURITIES AND EXCHANGE...
Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings Mylan prepared to bring its...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.